Bone Marrow Diseases
Welcome,         Profile    Billing    Logout  
 186 Companies   244 Products   244 Products   91 Mechanisms of Action   17 Trials   2576 News 


«12345678910111213...5253»
  • ||||||||||  decitabine / Generic mfg.
    Trial completion:  Phase I, Dose Escalation Study of Decitabine (clinicaltrials.gov) -  Oct 15, 2018   
    P1,  N=3, Completed, 
    Phase classification: P1 --> P2 Active, not recruiting --> Completed
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Enrollment change, Trial completion date, Combination therapy:  Nilotinib Plus Pegylated Interferon-?2b in CML (clinicaltrials.gov) -  Oct 12, 2018   
    P2,  N=20, Terminated, 
    Active, not recruiting --> Completed N=60 --> 20 | Trial completion date: Sep 2016 --> May 2016
  • ||||||||||  CC-90002 / Inhibrx, BMS
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) -  Oct 9, 2018   
    P1,  N=28, Terminated, 
    Recruiting --> Active, not recruiting N=71 --> 28 | Trial completion date: Jul 2019 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Jul 2018; Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion
  • ||||||||||  CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Gene therapy:  WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) -  Oct 2, 2018   
    P1/2,  N=7, Completed, 
    N=71 --> 28 | Trial completion date: Jul 2019 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Jul 2018; Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion Recruiting --> Completed | N=18 --> 7 | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: May 2019 --> May 2018
  • ||||||||||  CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients (clinicaltrials.gov) -  Oct 2, 2018   
    P1/2,  N=3, Completed, 
    Recruiting --> Completed | N=18 --> 7 | Trial completion date: Oct 2019 --> May 2018 | Trial primary completion date: May 2019 --> May 2018 Recruiting --> Completed | N=25 --> 3 | Trial completion date: Jul 2019 --> May 2018 | Trial primary completion date: Jul 2019 --> May 2018
  • ||||||||||  Jakafi (ruxolitinib) / Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
    Trial completion, Trial completion date, Trial primary completion date:  Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (clinicaltrials.gov) -  Oct 2, 2018   
    P1/2,  N=5, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Nov 2017 Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Apr 2018 | Trial primary completion date: Feb 2019 --> Mar 2018
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy:  Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q (clinicaltrials.gov) -  Sep 26, 2018   
    P2,  N=2, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Apr 2018 | Trial primary completion date: Feb 2019 --> Mar 2018 N=144 --> 2 | Trial completion date: May 2021 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Sep 2018; "the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)"
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  EVITA-Pilot: Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study (clinicaltrials.gov) -  Sep 24, 2018   
    P=N/A,  N=20, Completed, 
    N=144 --> 2 | Trial completion date: May 2021 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Sep 2018; "the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)" Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2018 --> May 2017 | Trial primary completion date: Aug 2018 --> May 2017
  • ||||||||||  azacitidine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Combination therapy:  A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (clinicaltrials.gov) -  Sep 14, 2018   
    P1,  N=23, Completed, 
    Recruiting --> Completed | N=40 --> 20 | Trial completion date: Dec 2018 --> May 2017 | Trial primary completion date: Aug 2018 --> May 2017 Active, not recruiting --> Completed | N=36 --> 23 | Trial completion date: Dec 2018 --> Aug 2018
  • ||||||||||  pracinostat (SB939) / Helsinn, MEI, Menarini
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome (clinicaltrials.gov) -  Sep 13, 2018   
    P2,  N=102, Completed, 
    Active, not recruiting --> Completed | N=36 --> 23 | Trial completion date: Dec 2018 --> Aug 2018 Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2015 | Active, not recruiting --> Completed
  • ||||||||||  mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
    Phase classification, Trial primary completion date:  Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT (clinicaltrials.gov) -  Sep 12, 2018   
    P1,  N=1, Terminated, 
    Trial completion date: Dec 2017 --> Nov 2016 | Trial primary completion date: Dec 2017 --> Nov 2015 | Active, not recruiting --> Completed Phase classification: P1/2 --> P1 | Trial primary completion date: Jul 2018 --> Apr 2017
  • ||||||||||  arsenic trioxide / Generic mfg.
    Trial completion date, Trial termination:  Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) -  Sep 6, 2018   
    P1,  N=7, Terminated, 
    Active, not recruiting --> Completed Trial completion date: Sep 2020 --> Aug 2018 | Active, not recruiting --> Terminated; Lack of enrollment and limited funding
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial suspension, Post-transplantation:  Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT (clinicaltrials.gov) -  Sep 5, 2018   
    P2,  N=60, Suspended, 
    Trial completion date: Sep 2020 --> Aug 2018 | Active, not recruiting --> Terminated; Lack of enrollment and limited funding Recruiting --> Suspended
  • ||||||||||  cyclophosphamide / Generic mfg.
    Phase classification, Trial termination:  Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) -  Aug 20, 2018   
    P1,  N=14, Terminated, 
    Recruiting --> Terminated; Accrual factor Phase classification: P=N/A --> P1 | Active, not recruiting --> Terminated; Poor accrual
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Trial termination:  Telemonitoring Study - for Chronic Myeloid Leukemia (CML) (clinicaltrials.gov) -  Aug 13, 2018   
    P=N/A,  N=14, Terminated, 
    Phase classification: P=N/A --> P1 | Active, not recruiting --> Terminated; Poor accrual Completed --> Terminated; Terminated due to lack of funding
  • ||||||||||  volasertib (NBL-001) / Oncoheroes, Notable Labs
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy:  Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (clinicaltrials.gov) -  Aug 9, 2018   
    P1,  N=1, Terminated, 
    N=48 --> 27 | Active, not recruiting --> Terminated; Study was terminated due to lack of funding N=70 --> 1 | Trial completion date: Nov 2016 --> Jul 2016 | Trial primary completion date: Nov 2016 --> Jun 2016
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Trial completion:  Nilotinib in PH+, BCR-, ABL+ CML Patients (clinicaltrials.gov) -  Aug 6, 2018   
    P3,  N=109, Completed, 
    Terminated --> Completed Active, not recruiting --> Completed
  • ||||||||||  Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study (clinicaltrials.gov) -  Jul 26, 2018   
    P=N/A,  N=0, Withdrawn, 
    N=300 --> 650 | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2018 --> May 2019 N=25 --> 0 | Trial completion date: Jul 2021 --> May 2018 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2020 --> May 2018
  • ||||||||||  PLX51107 / Daiichi Sankyo
    Phase classification, Trial completion date, Trial primary completion date, Metastases:  A Study of PLX51107 in Advanced Malignancies (clinicaltrials.gov) -  Jul 9, 2018   
    P1b/2a,  N=60, Recruiting, 
    N=11 --> 45 Phase classification: P1b --> P1b/2a | Trial completion date: Mar 2018 --> May 2019 | Trial primary completion date: Jan 2018 --> Jan 2019
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Phase classification, Enrollment change, Trial termination, Post-transplantation:  Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells (clinicaltrials.gov) -  Jun 27, 2018   
    P1/2,  N=10, Terminated, 
    Recruiting --> Completed Phase classification: P=N/A --> P1/2 | N=24 --> 10 | Active, not recruiting --> Terminated; Safety
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Post-transplantation:  Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies (clinicaltrials.gov) -  Jun 25, 2018   
    P1,  N=2, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=18 --> 2 | Trial completion date: Mar 2019 --> May 2018 | Trial primary completion date: Mar 2019 --> May 2018
  • ||||||||||  imatinib / Generic mfg.
    Enrollment change, Trial completion date, Trial termination:  IDEAL: A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients (clinicaltrials.gov) -  Jun 15, 2018   
    P4,  N=55, Terminated, 
    Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019 N=150 --> 55 | Trial completion date: Aug 2019 --> Jan 2018 | Active, not recruiting --> Terminated; Sponsor's decision to halt the study.
  • ||||||||||  tosedostat (CHR-2797) / SOBI
    Enrollment change:  Study of Clinical Efficacy and Safety of Tosedostat in MDS (clinicaltrials.gov) -  Jun 12, 2018   
    P2,  N=12, Completed, 
    Active, not recruiting --> Completed | N=61 --> 121 N=80 --> 12
  • ||||||||||  Coversin SC (nomacopan SC) / Akari Therap
    Trial completion, Trial completion date:  Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) (clinicaltrials.gov) -  Jun 4, 2018   
    P2,  N=6, Completed, 
    N=80 --> 12 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018